Bioton Stock

Bioton Equity

The Equity of Bioton (BIO.WA) as of Aug 5, 2026.

Equity

0.00PLN

Last updated:

In 2026, Bioton's equity was 0.00 PLN, a % increase from the 590.55 M PLN equity in the previous year.

Access this data via the Eulerpool API

Bioton Stock analysis

What does Bioton do? Bioton SA is a leading Polish biotechnology company specializing in the development of innovative drugs, diagnostics, and medical devices. The company was founded in 1989 and has since achieved remarkable success. Bioton is headquartered in Poland and employs approximately 1000 people worldwide. The company is listed on the Warsaw Stock Exchange and is supported by renowned investors. Business model Bioton operates various business divisions, including research and development, production, sales, as well as marketing and distribution. The company collaborates closely with leading academic institutions and research organizations and invests significant resources in the development of new groundbreaking technologies and products. The company's products and services are distributed and used in over 60 countries worldwide. Divisions Bioton is divided into three main business sectors, including biopharmaceuticals, diagnostics, and medical devices. Biopharmaceuticals Bioton is known for its biopharmaceuticals, particularly insulin and insulin analogs. Insulin is a hormone produced by the body to regulate blood sugar levels. Bioton offers various insulin products, including human insulin, insulin glargine, and insulin aspart. These products are approved for the treatment of diabetes mellitus and are distributed in over 50 countries worldwide. Diagnostics Bioton is also involved in the development and production of diagnostics. The company offers various testing systems for the diagnosis of infectious diseases, allergies, and autoimmune diseases. The product line also includes in vitro diagnostics that are used for medical therapy monitoring and disease detection. Medical devices Bioton also manufactures and distributes medical devices such as insulin pumps and blood glucose meters. These devices are designed for people with diabetes and assist in accurate insulin dosing and blood sugar level monitoring. Products In addition to insulin and insulin analogs, Bioton also produces a wide range of other drugs, including growth hormones, as well as follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These hormones are used for the treatment of infertility. Bioton is also involved in the development of novel technologies such as RNA interference (RNAi) and genomic research. The company invests significantly in innovative research projects aimed at the development of groundbreaking drugs and therapies. In conclusion, Bioton SA is a highly innovative biotechnology company with a wide range of products and a focus on research and development. The company operates in the global market and collaborates closely with renowned institutions and research organizations. Bioton's business model is based on the development of innovative technologies and products aimed at improving the quality of life for people worldwide. Bioton is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Bioton's Equity

Bioton's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Bioton's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Bioton's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Bioton's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Bioton’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Bioton stock

On Eulerpool you can find the complete historical development of The Equity Bioton since 2006 – with annual values, charts, and detailed analysis.

The Equity's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Bioton historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Bioton

All Key Metrics — Bioton